PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors
PET has an established role in the initial staging of patients with newly diagnosed lung and gastrointestinal tumors.PET avidity is described with both maximum and mean standardized uptake values.Malignant cells have increased activity on PET, defined as the standardized uptake value (SUV), with increased uptake of FDG in tumor due to elevated levels of GLUT receptors, elevated intracellular levels of hexokinase and increased rates of glycolysis. However, there is a subset of patients with lung and gastrointestinal tumors that are not PET avid.These patients may present with clinically and systemically aggressive disease with a declining performance status and/or weight loss.
Checked against the public recordLast updated Apr 21, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Texas Southwestern Medical Center
- Interventions being studied
- Other: Retrospective study
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: Patients with histologically proven lung and gastrointestinal cancers, stages I-IV with PET and/or CT within 6 weeks of diagnosis. Exclusion Criteria: There will be no absolute exclusion criteria as long as the inclusion criteria have been met.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UT Southwestern Medical CentreDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 21, 2026. Always confirm current availability with the study team.